Department of Pathology
Brigham and Women's Hospital
A teaching Affliate of Harvard Medical School
 

Name and Present Position:

SHUJI OGINO, Associate Pathologist

Address:

Brigham and Women's Hospital, Department of Pathology, 75 Francis Street, Boston, MA
E-mail: shuji_ogino@dfci.harvard.edu

Medical School (including school name, date and degree awarded):

1993 M.D., University of Tokyo, Japan
 

Graduate Medical Education (including dates and institution of internships, residencies, fellowships, etc.):

1995-97 Residency in Anatomic and Clinical Pathology, Allegheny General Hospital
1997-99 Residency in Anatomic and Clinical Pathology, Case Western Reserve University and University Hospitals of Cleveland
1999-01 Molecular Pathology Fellowship and Post-doctoral Research, University of Pennsylvania
2001 Ph.D., University of Tokyo, Japan

Certification (list all):

2000 American Board of Pathology (Anatomic Pathology and Clinical Pathology)
2001 American Board of Clinical Chemistry (Molecular Diagnostics)
2003 American Board of Pathology and American Board of Medical Genetics (Molecular Genetic Pathology)

Current Academic Appointment:

Assistant Professor of Pathology, Harvard Medical School

Current Medical Staff Appointments:

Associate Pathologist, Brigham and Women's Hospital
Independent Investigator, Dana-Farber Cancer Institute
Member, Cancer Epidemiology Program and Gastrointestinal Malignancies Program, Dana-Farber / Harvard Cancer Center

Concise Summary of Role in the Program:

Serves as an attending pathologist in molecular diagnostics, and signs out with residents and fellows.

Conducts molecular pathology and epidemiology research on colorectal and pancreatic cancers as a Principal Investigator at the Center for Molecular Oncologic Pathology (CMOP) of the Dana-Farber Cancer Institute (DFCI). The projects utilize large prospective cohort studies, the Nurses' Health Study (N=121,700) and the Health Professionals Follow-up Study (N=51,500), as well as clinical trials at DFCI. The epidemiology research is conducted in collaboration with the Harvard School of Public Health, and the Channing Laboratory of the Brigham and Women's Hospital.

Serves as a faculty member for Harvard Medical School (HMS) Molecular Genetic Pathology Training Program and Genetics Training Program, and as Guest Faculty for Master of Science Program in Genetic Counseling at Brandeis University and Boston University.

Selected Bibliography (The symbol * indicates that Ogino S is the corresponding author):

  • Ogino S,* Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS.
    LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. Int J Cancer 2008: in press.
  • Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S.* CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol 2008: in press (published online).
  • Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S.* WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008: in press (published online).
  • Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S.* Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008: in press.
  • Ogino S,* Goel A. Molecular classification and correlates in colorectal cancer [review]. J Mol Diagn 2008; 10: 13-27.
  • Park DY, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY, Chung DC, Rueda BR, Zukerberg LR. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol 2007; 171: 1509-1519.
  • Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S.* IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype and p53. Neoplasia 2007; 9: 1091-1098.
  • Ogino S,* Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007; 28: 1985-1990.
  • Ogino S,* Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56: 1564-1571.
  • Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S*. Correlation of -catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype in colorectal cancer. Neoplasia 2007; 9: 569-577.
  • Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl J Med 2007; 356: 2131-2142. (I am the sole pathologist in this study).
  • Ogino S,* Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007; 7: 72 (electronic paper, 9 pages).
  • Ogino S,* Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer using a large population-based sample. J Mol Diagn 2007; 9: 305-314.
  • Ogino S,* Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007; 450: 529-537.
  • Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007; 38: 842-849.
  • Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol 2007; 38: 614-620.
  • Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007;38:585-592.
  • Ogino S,* Gulley ML, den Dunnen JT, Wilson RB, Association for Molecular Pathology Training and Education Committee. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 2007;9:1-6.
  • Ogino S,* Wilson RB, Gold B, Flodman P. Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance. J Genet Counsel 2007;16(1):29-39.
  • Ogino S,* Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B / KIP1) in colorectal cancer is associated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
  • Ogino S, Wilson RB. Bayesian analysis (chapter). In Molecular Pathology in Clinical Practice, edited by Leonard DG et al. Springer 2007.
  • Ogino S,* Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-588.
  • Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66(17): 8625-8632.
  • Ogino S,* Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of p21 (CDKN1A / CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006; 210: 147-154.
  • Ogino S,* Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlations of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006; 30(9): 1175-1183.
  • Ogino S,* Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 2006; 19: 1083-1090.
  • Ogino S,* Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006; 8: 458-464.
  • Ogino S,* Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-217.
  • Ogino S,* Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68.
  • Ogino S,* Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55: 1000-1006.
  • Ogino S,* Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005; 11(18): 6650-6656.
  • Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer [editorial]. J Natl Cancer Inst 2005; 97(18): 1317-1319.